Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Renal Cell
As compared with interferon alfa, temsirolimus improved overall survival among patients with metastatic renal-cell carcinoma and a poor prognosis. The addition of temsirolimus to interferon did not improve survival. (ClinicalTrials.gov number, NCT00065468 [ClinicalTrials.gov].).